Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

BACKGROUND: Validated prognostic biomarkers for anti-angiogenic therapy using the anti-VEGF antibody Bevacizumab in ovarian cancer (OC) patients are still an unmet clinical need. The EGFR can contribute to cancer-associated biological mechanisms in OC cells including angiogenesis, but its targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Forlani, Luca, De Cecco, Loris, Simeon, Vittorio, Paolini, Biagio, Bagnoli, Marina, Cecere, Sabrina Chiara, Spina, Anna, Citeroni, Eleonora, Bignotti, Eliana, Lorusso, Domenica, Arenare, Laura, Russo, Daniela, De Angelis, Carmine, Ardighieri, Laura, Scognamiglio, Giosuè, Del Sesto, Michele, Tognon, Germana, Califano, Daniela, Schettino, Clorinda, Chiodini, Paolo, Perrone, Francesco, Mezzanzanica, Delia, Pignata, Sandro, Tomassetti, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088260/
https://www.ncbi.nlm.nih.gov/pubmed/37041632
http://dx.doi.org/10.1186/s13046-023-02651-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088260/
https://www.ncbi.nlm.nih.gov/pubmed/37041632
http://dx.doi.org/10.1186/s13046-023-02651-y

Ejemplares similares